Symbols

STOK

Stoke Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About STOK

Stoke Therapeutics, Inc.

A biotech company that develops antisense oligonucleotide medicines to target RNA splicing to enhance gene expression

Industry

Biological Technology

Established Date

Listing Date

06/19/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

128

Fiscal Year Ends

12-31

Website

www.stoketherapeutics.com

Security Type

Common stock

Office address

45 Wiggins Avenue, Bedford, MA 01730

Business

Introduction

Stoke Therapeutics, Inc., was founded in June 2014 and was incorporated under the laws of the State of Delaware. The company is an early-stage biopharmaceutical company that has pioneered new ways to treat the underlying causes of serious genetic diseases by precisely up-regulating protein expression. The company is developing novel antisense oligonucleotide (ASO) drugs that target ribonucleic acid or RNA and modulate precursor-messenger RNA or pre-mRNA, up-regulating protein expression to near normal levels with appropriate specificity when needed. The company uses a proprietary technology platform to target enhanced nuclear gene output, or TANGO, to design ASO to up-regulate the expression of proteins in individual patients' genes. The Company's methods are designed to deliver disease-modifying therapies to a wide range of relevant tissues, including the central nervous system, or central nervous system, eyes, kidneys and liver, in a highly precise, durable and controllable manner.

Company Financials

EPS

STOK has released its 2025 Q3 earnings. EPS was reported at -0.65, versus the expected -0.59, missing expectations. The chart below visualizes how STOK has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

STOK has released its 2025 Q3 earnings report, with revenue of 10.63M, reflecting a YoY change of 117.25%, and net profit of -38.35M, showing a YoY change of -45.09%. The Sankey diagram below clearly presents STOK's revenue sources and cost distribution.